Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Arbutus Biopharma (ABUS – Research Report), Neurocrine (NBIX – Research Report) and Bausch Health Companies (BHC – Research Report).
Arbutus Biopharma (ABUS)
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Arbutus Biopharma today and set a price target of $5.00. The company’s shares closed last Thursday at $2.68.
According to TipRanks.com, Arce is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Arbutus Biopharma with a $4.33 average price target, implying a 64.0% upside from current levels. In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $4.00 price target.
See the top stocks recommended by analysts >>
Neurocrine (NBIX)
In a report released today, Anupam Rama from J.P. Morgan maintained a Buy rating on Neurocrine, with a price target of $158.00. The company’s shares closed last Thursday at $139.83, close to its 52-week high of $148.37.
According to TipRanks.com, Rama is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Neurocrine with a $158.15 average price target, a 10.0% upside from current levels. In a report issued on April 23, Wells Fargo also upgraded the stock to Buy with a $170.00 price target.
Bausch Health Companies (BHC)
In a report released yesterday, Douglas Miehm from RBC Capital assigned a Hold rating to Bausch Health Companies, with a price target of $10.00. The company’s shares closed last Thursday at $8.09.
According to TipRanks.com, Miehm is a 1-star analyst with an average return of
Currently, the analyst consensus on Bausch Health Companies is a Hold with an average price target of $10.80, representing a 27.4% upside. In a report issued on April 29, Piper Sandler also assigned a Hold rating to the stock with a $9.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ABUS:
- Arbutus Biopharma CSO Sets Retirement Date
- Arbutus Biopharma Showcases Promising Q1 Results
- Arbutus Biopharma Announces Chief Scientific Officer’s Retirement
- Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
